Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to background maintenance therapy without the use of conditioning chemotherapy to drive B cell depletion and improve patient outcome.

The Company will also deliver an oral presentation on FT839, its next-generation, off-the-shelf dual-CAR T cell therapy designed to simultaneously target CD19 and CD38 to eliminate pathogenic B cells, plasma cells, and activated T and NK cells, while selectively sparing non-activated immune cells. This multi-antigen targeting approach is designed to offer a unique treatment option for patients with difficult-to-treat autoimmune diseases that are multicellular in pathology, including rheumatoid arthritis and type 1 diabetes.

Additionally, the Company will present preclinical data on FT836, its next-generation, off-the-shelf CAR T-cell therapy targeting the pan-tumor stress ligands MICA/B. FT836 is shown to demonstrate potent anti-tumor activity in preclinical studies across a broad range of liquid and solid tumors without the need for conditioning chemotherapy, and can be rationally combined with standard-of-care treatments, including monoclonal antibodies, immunomodulatory drugs, and chemotherapy for enhanced clinical efficacy.